vs
Side-by-side financial comparison of JFrog Ltd (FROG) and USANA HEALTH SCIENCES INC (USNA). Click either name above to swap in a different company.
USANA HEALTH SCIENCES INC is the larger business by last-quarter revenue ($250.2M vs $145.3M, roughly 1.7× JFrog Ltd). USANA HEALTH SCIENCES INC runs the higher net margin — 3.0% vs -10.5%, a 13.5% gap on every dollar of revenue. On growth, JFrog Ltd posted the faster year-over-year revenue change (25.2% vs -3.0%). Over the past eight quarters, JFrog Ltd's revenue compounded faster (20.4% CAGR vs 11.8%).
JFrog Ltd is a global DevOps technology provider that delivers end-to-end software release, artifact management, and security solutions. It serves clients across tech, finance, retail, and manufacturing sectors, helping teams streamline development and delivery workflows for cloud, on-premises, and hybrid infrastructure.
Usana Health Sciences, Inc., or USANA, is an American multi-level marketing company based in Salt Lake City, Utah. As of 2021, Usana was the 14th largest direct-selling company in the world by revenue. The company manufactures most of its nutritional products, dietary supplements, and skincare products at a Salt Lake City facility. Its products are sold in 24 countries via a network of independent distributors.
FROG vs USNA — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2027
| Metric | | |
|---|---|---|
| Revenue | $145.3M | $250.2M |
| Net Profit | $-15.2M | $7.5M |
| Gross Margin | 77.9% | 76.2% |
| Operating Margin | -14.7% | 5.5% |
| Net Margin | -10.5% | 3.0% |
| Revenue YoY | 25.2% | -3.0% |
| Net Profit YoY | 34.4% | -20.0% |
| EPS (diluted) | $-0.13 | $0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $250.2M | ||
| Q4 25 | $145.3M | $226.2M | ||
| Q3 25 | $136.9M | $213.7M | ||
| Q2 25 | $127.2M | $235.8M | ||
| Q1 25 | $122.4M | $249.5M | ||
| Q4 24 | $116.1M | $213.6M | ||
| Q3 24 | $109.1M | $200.2M | ||
| Q2 24 | $103.0M | — |
| Q1 26 | — | $7.5M | ||
| Q4 25 | $-15.2M | $180.0K | ||
| Q3 25 | $-16.4M | $-6.5M | ||
| Q2 25 | $-21.7M | $9.7M | ||
| Q1 25 | $-18.5M | $9.4M | ||
| Q4 24 | $-23.2M | $4.5M | ||
| Q3 24 | $-22.9M | $10.6M | ||
| Q2 24 | $-14.3M | — |
| Q1 26 | — | 76.2% | ||
| Q4 25 | 77.9% | 78.2% | ||
| Q3 25 | 77.4% | 77.2% | ||
| Q2 25 | 76.3% | 78.7% | ||
| Q1 25 | 75.3% | 79.0% | ||
| Q4 24 | 75.4% | 82.0% | ||
| Q3 24 | 75.0% | 80.4% | ||
| Q2 24 | 78.8% | — |
| Q1 26 | — | 5.5% | ||
| Q4 25 | -14.7% | 1.7% | ||
| Q3 25 | -15.8% | 0.6% | ||
| Q2 25 | -20.4% | 7.1% | ||
| Q1 25 | -18.8% | 6.3% | ||
| Q4 24 | -21.9% | 3.8% | ||
| Q3 24 | -27.4% | 7.8% | ||
| Q2 24 | -18.6% | — |
| Q1 26 | — | 3.0% | ||
| Q4 25 | -10.5% | 0.1% | ||
| Q3 25 | -12.0% | -3.1% | ||
| Q2 25 | -17.0% | 4.1% | ||
| Q1 25 | -15.1% | 3.8% | ||
| Q4 24 | -20.0% | 2.1% | ||
| Q3 24 | -21.0% | 5.3% | ||
| Q2 24 | -13.9% | — |
| Q1 26 | — | $0.41 | ||
| Q4 25 | $-0.13 | $-0.10 | ||
| Q3 25 | $-0.14 | $-0.36 | ||
| Q2 25 | $-0.19 | $0.52 | ||
| Q1 25 | $-0.16 | $0.49 | ||
| Q4 24 | $-0.21 | $0.23 | ||
| Q3 24 | $-0.21 | $0.56 | ||
| Q2 24 | $-0.13 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $704.4M | $162.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $887.4M | — |
| Total Assets | $1.3B | $739.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $162.8M | ||
| Q4 25 | $704.4M | $158.4M | ||
| Q3 25 | $651.1M | $145.3M | ||
| Q2 25 | $611.7M | $151.3M | ||
| Q1 25 | $563.5M | $179.6M | ||
| Q4 24 | $522.0M | $181.8M | ||
| Q3 24 | $467.8M | $364.9M | ||
| Q2 24 | $591.3M | — |
| Q1 26 | — | — | ||
| Q4 25 | $887.4M | — | ||
| Q3 25 | $859.4M | $528.1M | ||
| Q2 25 | $826.5M | $531.1M | ||
| Q1 25 | $800.0M | $529.8M | ||
| Q4 24 | $773.5M | $532.1M | ||
| Q3 24 | $756.2M | $533.1M | ||
| Q2 24 | $721.4M | — |
| Q1 26 | — | $739.0M | ||
| Q4 25 | $1.3B | $742.9M | ||
| Q3 25 | $1.3B | $726.6M | ||
| Q2 25 | $1.2B | $734.5M | ||
| Q1 25 | $1.2B | $746.6M | ||
| Q4 24 | $1.1B | $748.2M | ||
| Q3 24 | $1.1B | $671.3M | ||
| Q2 24 | $1.0B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $50.7M | — |
| Free Cash FlowOCF − Capex | $49.9M | — |
| FCF MarginFCF / Revenue | 34.3% | — |
| Capex IntensityCapex / Revenue | 0.6% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $142.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $50.7M | — | ||
| Q3 25 | $30.2M | $-2.0M | ||
| Q2 25 | $36.1M | $12.2M | ||
| Q1 25 | $28.8M | $15.5M | ||
| Q4 24 | $49.1M | $5.8M | ||
| Q3 24 | $27.6M | $29.5M | ||
| Q2 24 | $16.7M | — |
| Q1 26 | — | — | ||
| Q4 25 | $49.9M | — | ||
| Q3 25 | $28.8M | $-5.2M | ||
| Q2 25 | $35.5M | $7.2M | ||
| Q1 25 | $28.1M | $12.7M | ||
| Q4 24 | $48.5M | $4.0M | ||
| Q3 24 | $26.7M | $27.1M | ||
| Q2 24 | $16.0M | — |
| Q1 26 | — | — | ||
| Q4 25 | 34.3% | — | ||
| Q3 25 | 21.0% | -2.4% | ||
| Q2 25 | 27.9% | 3.0% | ||
| Q1 25 | 23.0% | 5.1% | ||
| Q4 24 | 41.8% | 1.9% | ||
| Q3 24 | 24.5% | 13.6% | ||
| Q2 24 | 15.5% | — |
| Q1 26 | — | — | ||
| Q4 25 | 0.6% | — | ||
| Q3 25 | 1.0% | 1.5% | ||
| Q2 25 | 0.5% | 2.1% | ||
| Q1 25 | 0.5% | 1.1% | ||
| Q4 24 | 0.5% | 0.8% | ||
| Q3 24 | 0.9% | 1.2% | ||
| Q2 24 | 0.7% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 1.27× | ||
| Q1 25 | — | 1.65× | ||
| Q4 24 | — | 1.29× | ||
| Q3 24 | — | 2.78× | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
